Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) shares shot up 11.8% during mid-day trading on Thursday . The stock traded as high as $7.95 and last traded at $7.95, with a volume of 117,867 shares traded. The stock had previously closed at $7.11.

Several brokerages recently issued reports on ADAP. Leerink Swann reiterated a “buy” rating on shares of Adaptimmune Therapeutics PLC – in a research report on Sunday, April 24th. Zacks Investment Research upgraded shares of Adaptimmune Therapeutics PLC – from a “hold” rating to a “buy” rating and set a $9.75 target price for the company in a research report on Tuesday, July 12th. Six equities research analysts have rated the stock with a buy rating, Adaptimmune Therapeutics PLC – presently has an average rating of “Buy” and a consensus target price of $15.94.

The stock has a 50-day moving average of $9.00 and a 200 day moving average of $8.77. The company’s market capitalization is $545.04 million.

Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) last issued its quarterly earnings results on Thursday, May 12th. The company reported ($0.22) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by $0.03. Equities research analysts predict that Adaptimmune Therapeutics PLC – will post ($1.12) EPS for the current fiscal year.

In other Adaptimmune Therapeutics PLC – news, Director Orbimed Advisors Llc purchased 1,712,400 shares of the company’s stock in a transaction dated Tuesday, May 24th. The shares were acquired at an average price of $10.42 per share, for a total transaction of $17,843,208.00. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Charles Elliott Sigal purchased 45,000 shares of the company’s stock in a transaction dated Wednesday, May 18th. The shares were acquired at an average price of $1.53 per share, for a total transaction of $68,850.00. Following the purchase, the director now directly owns 52,938 shares in the company, valued at $80,995.14. The disclosure for this purchase can be found here.

Several hedge funds and institutional investors have modified their holdings of the company. Marshall Wace LLP acquired a new position in shares of Adaptimmune Therapeutics PLC – during the fourth quarter valued at $1,700,000. Tekla Capital Management LLC increased its stake in shares of Adaptimmune Therapeutics PLC – by 5.3% in the fourth quarter. Tekla Capital Management LLC now owns 296,934 shares of the company’s stock valued at $3,581,000 after buying an additional 15,000 shares during the last quarter. Finally, Jennison Associates LLC increased its stake in shares of Adaptimmune Therapeutics PLC – by 0.3% in the fourth quarter. Jennison Associates LLC now owns 486,948 shares of the company’s stock valued at $5,873,000 after buying an additional 1,547 shares during the last quarter.

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.